Tumor Necrosis Factor Receptor Blocking Activity

Tumor Necrosis Factor Blocker

Arthritis, Juvenile

Arthritis, Rheumatoid

Colitis, Ulcerative

Crohn Disease

Spondylitis, Ankylosing

Uveitis

Arthritis, Psoriatic

Hidradenitis Suppurativa

<section class="Section" data-sectioncode="34089-3"><a name="section-10"></a><h1>11 DESCRIPTION</h1>Adalimumab is a tumor necrosis factor blocker. Adalimumab is a recombinant human IgG1 monoclonal antibody created using phage display technology resulting in an antibody with human derived heavy and light chain variable regions and human IgG1:k constant regions. Adalimumab is produced by recombinant DNA technology in a mammalian cell (Chinese Hamster Ovary (CHO)) expression system and is purified by a process that includes specific viral inactivation and removal steps. It consists of 1330 amino acids and has a molecular weight of approximately 148 kilodaltons. HUMIRA (adalimumab) injection is supplied as a sterile, preservative-free solution for subcutaneous administration. The drug product is supplied as either a single-dose, prefilled pen (HUMIRA Pen), as a single-dose, 1 mL prefilled glass syringe, or as a single-dose institutional use vial. Enclosed within the pen is a single-dose, 1 mL prefilled glass syringe. The solution of HUMIRA is clear and colorless, with a pH of about 5.2. Each 80 mg/0.8 mL prefilled syringe or prefilled pen delivers 0.8 mL (80 mg) of drug product. Each 0.8 mL of HUMIRA contains adalimumab (80 mg), mannitol (33.6 mg), polysorbate 80 (0.8 mg), and Water for Injection, USP. Each 40 mg/0.4 mL prefilled syringe or prefilled pen delivers 0.4 mL (40 mg) of drug product. Each 0.4 mL of HUMIRA contains adalimumab (40 mg), mannitol (16.8 mg), polysorbate 80 (0.4 mg), and Water for Injection, USP. Each 40 mg/0.8 mL prefilled syringe, prefilled pen, or single-dose institutional use vial delivers 0.8 mL (40 mg) of drug product. Each 0.8 mL of HUMIRA contains adalimumab (40 mg), citric acid monohydrate (1.04 mg), dibasic sodium phosphate dihydrate (1.22 mg), mannitol (9.6 mg), monobasic sodium phosphate dihydrate (0.69 mg), polysorbate 80 (0.8 mg), sodium chloride (4.93 mg), sodium citrate (0.24 mg) and Water for Injection, USP. Sodium hydroxide is added as necessary to adjust pH. Each 20 mg/0.2 mL prefilled syringe delivers 0.2 mL (20 mg) of drug product. Each 0.2 mL of HUMIRA contains adalimumab (20 mg), mannitol (8.4 mg), polysorbate 80 (0.2 mg), and Water for Injection, USP. Each 20 mg/0.4 mL prefilled syringe delivers 0.4 mL (20 mg) of drug product. Each 0.4 mL of HUMIRA contains adalimumab (20 mg), citric acid monohydrate (0.52 mg), dibasic sodium phosphate dihydrate (0.61 mg), mannitol (4.8 mg), monobasic sodium phosphate dihydrate (0.34 mg), polysorbate 80 (0.4 mg), sodium chloride (2.47 mg), sodium citrate (0.12 mg) and Water for Injection, USP. Sodium hydroxide is added as necessary to adjust pH. Each 10 mg/0.1 mL prefilled syringe delivers 0.1 mL (10 mg) of drug product. Each 0.1 mL of HUMIRA contains adalimumab (10 mg), mannitol (4.2 mg), polysorbate 80 (0.1 mg), and Water for Injection, USP. Each 10 mg/0.2 mL prefilled syringe delivers 0.2 mL (10 mg) of drug product. Each 0.2 mL of HUMIRA contains adalimumab (10 mg), citric acid monohydrate (0.26 mg), dibasic sodium phosphate dihydrate (0.31 mg), mannitol (2.4 mg), monobasic sodium phosphate dihydrate (0.17 mg), polysorbate 80 (0.2 mg), sodium chloride (1.23 mg), sodium citrate (0.06 mg) and Water for Injection, USP. Sodium hydroxide is added as necessary to adjust pH. </section>

Humira

0.8 ML adalimumab 50 MG/ML Auto-Injector

0.8 ML adalimumab 50 MG/ML Auto-Injector [Humira]

0.4 ML adalimumab 100 MG/ML Prefilled Syringe

0.4 ML adalimumab 100 MG/ML Prefilled Syringe [Humira]

0.8 ML adalimumab 100 MG/ML Prefilled Syringe

0.8 ML adalimumab 100 MG/ML Prefilled Syringe [Humira]

0.4 ML adalimumab 100 MG/ML Auto-Injector

0.4 ML adalimumab 100 MG/ML Auto-Injector [Humira]

0.1 ML adalimumab 100 MG/ML Prefilled Syringe

0.1 ML adalimumab 100 MG/ML Prefilled Syringe [Humira]

0.2 ML adalimumab 100 MG/ML Prefilled Syringe

0.2 ML adalimumab 100 MG/ML Prefilled Syringe [Humira]

0.8 ML adalimumab 100 MG/ML Auto-Injector

0.8 ML adalimumab 100 MG/ML Auto-Injector [Humira]

adalimumab

0.8 ML adalimumab 50 MG/ML Prefilled Syringe

0.8 ML adalimumab 50 MG/ML Prefilled Syringe [Humira]

Psoriasis (PsO)

Psoriatic Arthritis (PsA)

Ankylosing Spondylitis (AS)

Nonradiographic Axial Spondyloarthritis

Taltz

Juvenile Idiopathic Arthritis

Hidradenitis Suppurativa (HS)

Cosentyx

Siliq

Tremfya

Crohn's Disease (CD)

Ulcerative Colitis (UC)

Stelara

Skyrizi

Ilumya

Migraine

Cluster Headache

Migraine Prevention

Emgality

Qulipta

Acute Migraine

Ubrelvy

Nurtec ODT

Vyepti

Aimovig

Ajovy

Breast Cancer: HR+ (HER2-)

Verzenio

Ibrance

Kisqali

Atopic Dermatitis (Eczema)

Cibinqo

Eucrisa

Asthma (injectable)

Asthma OCS Dependent

Nasal Polyposis

Eosinophilic Esophagitis (EoE)

Prurigo Nodularis

Dupixent

Opzelura

Adbry

NSCLC ALK+ OR ROS1+ Disease

Lorbrena

Alecensa

Alunbrig

NSCLC cMET Mutation

Xalkori

Rheumatoid Arthritis (RA)

Xeljanz

Graft Versus Host Disease (GVHD)

Orencia

COVID-19 Treatment

Alopecia Areata

Olumiant

Multiple Sclerosis (MS)

Secondary Progressive Multiple Sclerosis

Zeposia

Rinvoq

Entyvio

Humira is a TNF-alpha inhibitor utilized to treat an extensive range of inflammatory conditions, including Rheumatoid Arthritis, psoriasis, ankylosing spondylitis, Crohn's disease, and Ulcerative colitis. However, Humira can suppress the immune system's ability to fight off infections caused by bacteria, fungi, or viruses, potentially increasing the risk of developing certain types of cancer.

Humira is FDA approved for the following indications: Rheumatoid Arthritis, Juvenile Idiopathic Arthritis, Psoriatic Arthritis, Ankylosing Spondylitis, Crohn’s Disease, Ulcerative Arthritis, Plaque Psoriasis, Hidradenitis Suppurativa, and Uveitis. 


Report Adverse Event 

Prescribing Information

Prescribing Information - Spanish

Medication Guide 

Submit MSL Request 

Pharmacy List 

Reimbursement Information 

Billing & Coding Guide 

Coverage Authorization Request 

Coverage Authorization Appeals

Letter of Medical Necessity 

Tiering Exception Letter

Formulary Exception Letter

Humira Complete Enrollment and Prescription Form: Dermatology (Adults)

Humira Complete Enrollment and Prescription Form: Gastroenterology (Adults)

Humira Complete Enrollment and Prescription Form: Rheumatology (Adults)

Humira Complete Enrollment and Prescription Form: Dermtology (Pediatrics)

Humira Complete Enrollment and Prescription Form: Gastroenterology (Pediatrics)

Humira Complete Enrollment and Prescription Form: Rheumatology (Pediatrics)

Enroll in Patient Savings Program 

Abbvie Patient Assistance Program Eligibility

Other HCP Resources 

Humira Complete Support Program 

Humira Complete App 

Cost Information

About Humira: Plaque Psoriasis 

Before and After: Plaque Psoriasis 

Taking Humira: Plaque Psoriasis

Doctor Discussion Guide: Plaque Psoriasis

About Humira: Psoriatic Arthritis 

Doctor Discussion Guide: Psoriatic Arthritis 

About Humira: Rheumatoid Arthritis 

Doctor Discussion Guide: Rheumatoid Arthritis 

About Humira: Hidradenitis Suppurativa

Patient Stories: Hidradenitis Suppurativa

Taking Humira: Hidradenitis Suppurativa

Doctor Discussion Guide: Hidradenitis Suppurativa

FAQs: Hidradenitis Suppurativa

About Humira: Ankylosing Spondylitis 

About Humira: Polyarticular Juvenile Idiopathic Arthritis (JIA)

FAQs: PsO, PsA, AS, RA, JIA, UC, CD

About Humira: Non-Infectious Uveitis

FAQs: Non-Infectious Uveitis 

Taking Humira: Non-Infectious Uveitis

Doctor Discussion Guide: Non-Infectious Uveitis

About Humira: Ulcerative Colitis 

Patient Stories: Ulcerative Colitis 

Taking Humira: Ulcerative Colitis 

Doctor Discussion Guide: Ulcerative Colitis 

About Humira: Pediatric Ulcerative Colitis 

FAQs: Pediatric Ulcerative Colitis 

Taking Humira: Pediatric Ulcerative Colitis 

Patient Brochure: Pediatric Ulcerative Colitis & Pediatric Crohn's Disease 

About Humira: Crohn's Disease 

Patient Stories: Crohn's Disease 

Taking Humira: Crohn's Disease 

Doctor Discussion Guide: Crohn's Disease

About Humira: Pediatric Crohn's Disease 

FAQs: Pediatric Crohn's Disease 

Taking Humira: Pediatric Crohn's Disease

Instructions For Use: Plaque Psoriasis 

Instructions For Use: Hidradenitis Suppurativa

Instructions For Use: Psoriatic Arthritis 

Instructions For Use: Rheumatoid Arthritis 

Instructions For Use: Ankylosing Spondylitis 

Instructions For Use: Polyarticular Juvenile Idiopathic Arthritis (JIA)

Instructions For Use: Uveitis

Instructions For Use: Crohn's Disease 

Instructions For Use: Pediatric Crohn's Disease 

Instructions For Use: Ulcerative Colitis

Instructions For Use: Pediatric Ulcerative Colitis 